Do analysts prefer CARM or EVGN?

Carisma Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 19,130.77%. Given Carisma Therapeutics' higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts prefer CARM or HEPA?

Carisma Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 19,130.77%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend WINT or CARM?

Carisma Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 19,130.77%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Windtree Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Windtree Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend CARM or BPTSY?

Carisma Therapeutics presently has a consensus target price of $1.00, suggesting a potential upside of 19,130.77%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Biophytis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, CARM or BPTSY?

Biophytis has lower revenue, but higher earnings than Carisma Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Carisma Therapeutics $10.77M 0.02 -$60.48M $0.73 0.01 Biophytis N/A N/A -$18.43M N/A N/A

Is CARM or BPTSY more profitable?

Biophytis has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics -254.28% N/A -192.17% Biophytis N/A N/A N/A

Is CARM or CERO more profitable?

CERo Therapeutics has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics -254.28% N/A -192.17% CERo Therapeutics N/A N/A -209.40%

Carisma Therapeutics (CARM) Competitors

$0.0052 0.00 (-8.77%)

As of 07/17/2026 12:48 PM Eastern

Compare

CARM vs. EVGN, HEPA, WINT, BPTSY, and CERO

Should you buy Carisma Therapeutics stock or one of its competitors? MarketBeat compares Carisma Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Carisma Therapeutics include Evogene (EVGN), Hepion Pharmaceuticals (HEPA), Windtree Therapeutics (WINT), Biophytis (BPTSY), and CERo Therapeutics (CERO). These companies are all part of the "medical" sector.

How does Carisma Therapeutics compare to Evogene?

Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.02	-$60.48M	$0.73	0.01
Evogene	$3.85M	1.42	-$8.48M	-$1.39	N/A

In the previous week, Evogene had 3 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.85 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Evogene	Positive

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -638.12%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Evogene	-638.12%	-158.82%	-80.37%

Carisma Therapeutics has a beta of -9.34, suggesting that its share price is 1,034% less volatile than the broader market. Comparatively, Evogene has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Carisma Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 19,130.77%. Given Carisma Therapeutics' higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Evogene beats Carisma Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Carisma Therapeutics compare to Hepion Pharmaceuticals?

Carisma Therapeutics (NASDAQ:CARM) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Hepion Pharmaceuticals	Neutral

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Hepion Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Carisma Therapeutics has a beta of -9.34, suggesting that its stock price is 1,034% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Carisma Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 19,130.77%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Hepion Pharmaceuticals has lower revenue, but higher earnings than Carisma Therapeutics. Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.02	-$60.48M	$0.73	0.01
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

Summary

Carisma Therapeutics beats Hepion Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Carisma Therapeutics compare to Windtree Therapeutics?

Windtree Therapeutics (NASDAQ:WINT) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Windtree Therapeutics has higher earnings, but lower revenue than Carisma Therapeutics. Windtree Therapeutics is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Windtree Therapeutics	N/A	N/A	-$1.79M	-$8.77	N/A
Carisma Therapeutics	$10.77M	0.02	-$60.48M	$0.73	0.01

Windtree Therapeutics has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Windtree Therapeutics	N/A	-207.34%	-50.19%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Carisma Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 19,130.77%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Windtree Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Windtree Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Windtree Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.34, indicating that its stock price is 1,034% less volatile than the broader market.

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Windtree Therapeutics	Neutral
Carisma Therapeutics	Neutral

Summary

Carisma Therapeutics beats Windtree Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Carisma Therapeutics compare to Biophytis?

Carisma Therapeutics (NASDAQ:CARM) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Carisma Therapeutics presently has a consensus target price of $1.00, suggesting a potential upside of 19,130.77%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Biophytis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Carisma Therapeutics has a beta of -9.34, meaning that its share price is 1,034% less volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its share price is 146% more volatile than the broader market.

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 3.7% of Biophytis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Biophytis	Neutral

Biophytis has lower revenue, but higher earnings than Carisma Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.02	-$60.48M	$0.73	0.01
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Biophytis has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Biophytis	N/A	N/A	N/A

Summary

Carisma Therapeutics beats Biophytis on 6 of the 10 factors compared between the two stocks.

How does Carisma Therapeutics compare to CERo Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CERo Therapeutics has lower revenue, but higher earnings than Carisma Therapeutics. CERo Therapeutics is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.02	-$60.48M	$0.73	0.01
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A

Carisma Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 19,130.77%. CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 272,627.27%. Given CERo Therapeutics' higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than Carisma Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

CERo Therapeutics has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
CERo Therapeutics	N/A	N/A	-209.40%

Carisma Therapeutics has a beta of -9.34, indicating that its share price is 1,034% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.13, indicating that its share price is 87% less volatile than the broader market.

In the previous week, CERo Therapeutics had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 2 mentions for CERo Therapeutics and 0 mentions for Carisma Therapeutics. CERo Therapeutics' average media sentiment score of 0.59 beat Carisma Therapeutics' score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
CERo Therapeutics	Positive

Summary

Carisma Therapeutics beats CERo Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Carisma Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARM vs. The Competition

Export

Metric	Carisma Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$218K	$3.03B	$6.89B	$12.43B
Dividend Yield	N/A	2.06%	2.67%	8.84%
P/E Ratio	0.01	19.91	27.13	23.90
Price / Sales	0.02	350.00	523.63	91.06
Price / Cash	N/A	57.21	51.46	60.07
Price / Book	-0.01	4.26	10.69	6.18
Net Income	-$60.48M	$65.46M	$3.59B	$331.73M
7 Day Performance	N/A	-3.17%	-2.17%	-2.09%
1 Month Performance	N/A	0.74%	1.63%	-2.19%
1 Year Performance	N/A	19.10%	25.56%	17.20%

Carisma Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARM Carisma Therapeutics	1.9166 of 5 stars	$0.01 -8.8%	$1.00 +19,130.8%	-98.7%	$218K	$10.77M	0.01	20
EVGN Evogene	1.5483 of 5 stars	$0.48 +4.0%	N/A	-52.7%	$4.05M	$3.85M	N/A	140	News Coverage
HEPA Hepion Pharmaceuticals	N/A	$0.06 flat	N/A	+40.2%	$686K	N/A	N/A	20	Gap Down
WINT Windtree Therapeutics	N/A	$0.01 -6.4%	N/A	-98.7%	$589K	N/A	N/A	30	Gap Up
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARM) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, HEPA, WINT, BPTSY, and CERO

How does Carisma Therapeutics compare to Evogene?

Summary

How does Carisma Therapeutics compare to Hepion Pharmaceuticals?

Summary

How does Carisma Therapeutics compare to Windtree Therapeutics?

Summary

How does Carisma Therapeutics compare to Biophytis?

Summary

How does Carisma Therapeutics compare to CERo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, HEPA, WINT, BPTSY, and CERO

How does Carisma Therapeutics compare to Evogene?

Which has preferable valuation and earnings, CARM or EVGN?

Does the media refer more to CARM or EVGN?

Is CARM or EVGN more profitable?

Which has more volatility & risk, CARM or EVGN?

Do analysts prefer CARM or EVGN?

Do insiders & institutionals have more ownership in CARM or EVGN?

Summary

How does Carisma Therapeutics compare to Hepion Pharmaceuticals?

Does the media refer more to CARM or HEPA?

Do insiders and institutionals have more ownership in CARM or HEPA?

Is CARM or HEPA more profitable?

Which has more risk and volatility, CARM or HEPA?

Do analysts prefer CARM or HEPA?

Which has stronger earnings & valuation, CARM or HEPA?

Summary

How does Carisma Therapeutics compare to Windtree Therapeutics?

Which has higher valuation and earnings, WINT or CARM?

Is WINT or CARM more profitable?

Do analysts recommend WINT or CARM?

Do institutionals & insiders have more ownership in WINT or CARM?

Which has more volatility & risk, WINT or CARM?

Does the media prefer WINT or CARM?

Summary

How does Carisma Therapeutics compare to Biophytis?

Do analysts recommend CARM or BPTSY?

Which has more risk and volatility, CARM or BPTSY?

Do insiders & institutionals hold more shares of CARM or BPTSY?

Does the media refer more to CARM or BPTSY?

Which has better valuation & earnings, CARM or BPTSY?

Is CARM or BPTSY more profitable?

Summary

How does Carisma Therapeutics compare to CERo Therapeutics?

Do institutionals & insiders believe in CARM or CERO?

Which has better valuation and earnings, CARM or CERO?

Do analysts rate CARM or CERO?

Is CARM or CERO more profitable?

Which has more risk and volatility, CARM or CERO?

Does the media favor CARM or CERO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools